Mandate

Vinge has advised Egetis Therapeutics in connection with a combined financing comprising an equity private placement and debt financing

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a combined financing comprising a SEK 172 million equity private placement and a SEK 290 million debt financing.

Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson, Lorin Arabi and Isabell Bitar (Capital Markets and Public M&A) and of Albert Wållgren, Arvid Weimers and Ida Redander (Banking and finance).

Related

Vinge has advised Lagercrantz Group on the acquisition of Sit Right and Enskede Hydraul

Lagercrantz Group AB (publ) has acquired 70 percent of the shares in the two Swedish companies Sit Right AB and Enskede Hydraul AB, which are leading operators in products and aftermarket parts for forestry and construction machinery in Europe.
November 07, 2025

Vinge advises the founders of NOOS Digital in connection with the merger with Rocket Revenue and 56K Digital

Following the recent merger between Rocket Revenue and 56K Digital, the group now takes its next step by joining forces with NOOS Digital. The three companies will integrate into one of the Nordic region’s most comprehensive partners for digital transformation and business acceleration.
November 04, 2025

Vinge advises Setra Trävaror in conjunction with the sale of Malå Såg to HS Timber

The Austrian company HS Timber Group has entered into an agreement to acquire 100 per cent of the shares in the Swedish wood processing company Malå Såg AB from Setra Trävaror AB, a subsidiary of Setra Group AB. The transaction remains subject to approval from the relevant public authorities.
October 29, 2025